Dalbavancin use in an academic medical centre and associated cost savings

Amber C. Streifel, Monica Sikka, Christina D. Bowen, James S. Lewis

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.

Original languageEnglish (US)
JournalInternational Journal of Antimicrobial Agents
DOIs
StateAccepted/In press - Jan 1 2019

Keywords

  • Dalbavancin
  • Gram-positive infection
  • OPAT
  • Outpatient parenteral antimicrobial therapy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Dalbavancin use in an academic medical centre and associated cost savings'. Together they form a unique fingerprint.

  • Cite this